Persisting burden and challenges of rheumatic heart disease.
Acute rheumatic fever
Cardiology
Global burden of diseases
Global health
Prevention
Rheumatic heart disease
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
07 09 2021
07 09 2021
Historique:
received:
16
03
2021
revised:
02
05
2021
accepted:
13
06
2021
pubmed:
16
7
2021
medline:
12
10
2021
entrez:
15
7
2021
Statut:
ppublish
Résumé
Rheumatic heart disease (RHD) is the result of episodes of acute rheumatic fever with valvular (and other cardiac) damage caused by an abnormal immune response to group A streptococcal infections, usually during childhood and adolescence. As a result of improved living conditions and the introduction of penicillin, RHD was almost eradicated in the developed world by the 1980s. However, being a disease of poverty, its burden remains disproportionately high in the developing world, despite being a fundamentally preventable disease. Rheumatic heart disease generates relatively little attention from the medical and science communities, in contrast to other common infectious problems (such as malaria, HIV, tuberculosis), despite the major cardiovascular morbidity/mortality burden imposed by RHD. This relative neglect and paucity of funding have probably contributed to limited fundamental medical advances in this field for over 50 years. Given the importance of prevention before the onset of major valvular damage, the main challenges for RHD prevention are improving social circumstances, early diagnosis, and effective delivery of antibiotic prophylaxis. Early identification through ultrasound of silent, subclinical rheumatic valve lesions could provide an opportunity for early intervention. Simple echocardiographic diagnostic criteria and appropriately trained personnel can be valuable aids in large-scale public health efforts. In addition, a better understanding of the immunogenic determinants of the disease may provide potential routes to vaccine development and other novel therapies.
Identifiants
pubmed: 34263296
pii: 6321664
doi: 10.1093/eurheartj/ehab407
doi:
Substances chimiques
Penicillins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3338-3348Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.